tissue is a shared feature for all types of cancer. However, the impact of a cancer environment on normal tissue stem and progenitor cells has not been thoroughly investigated. We began to address this important issue by studying the kinetics and functions of hematopoietic stem and progenitor cells in mice with Notch1-induced leukemia.
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INTRODUCTION
The predominant outgrowth of malignant cells over their normal counterparts in a given tissue is a shared feature for all types of cancer. While many intrinsic and extrinsic factors have been implicated in cancer development, the impact of a cancer environment on normal tissue stem and progenitor cells has been poorly understood. Like other cancers, leukemia is caused by both intrinsic factors, such as the aberrant expression of oncogenes or tumor suppressors, and extrinsic factors, such as immune dysfunction, neo-vasculature and other tumor-promoting microenvironmental cues in the hematopoietic system. Leukemia stem cells (LSCs) are thought to play a key role in the initiation, and possibly the maintenance, of leukemia. [1] [2] [3] During leukemogenesis, LSCs outcompete their normal counterparts, namely hematopoietic stem cells (HSCs), and become dominant by acquiring an increased capacity for self-renewal coupled with decreased levels of cell death or a disrupted differentiation program. 4 Thus, the clinical manifestations of leukemia are largely determined by the competition between LSCs and normal HSCs.
HSCs give rise to all types of mature blood and immune cells, and these mature cells provide environmental factors that can also influence leukemogenesis. Deregulated hematopoiesis can lead to significantly decreased numbers of blood cells and to anemia, infection and hemorrhage, all of which are directly responsible for the poor life quality and increased mortality of cancer patients. Moreover, because autologous HSC transplantation (auto-HSCT) has been used with chemotherapy and radiotherapy to treat hematological malignancies and other solid tumors, the For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -4 -quality of normal HSCs from a cancer patient may serve as a critical parameter for the ultimate success of auto-HSCT for the patient. Therefore, the impact of a leukemic environment on normal HSCs and hematopoietic progenitor cells (HPCs) during leukemogenesis is an issue of high significance. Studies along this line may have implications for other cancers as well.
In this study, we have examined the kinetics of normal HSCs and HPCs in the Notch1-induced murine T cell leukemia model. Our results demonstrate that hematopoietic cells in the leukemic environment are progressively decreased as measured by both phenotype and function.
However, the effects of the leukemic environment on HSC and HPC are distinct in that the repopulation potential of HSCs from the leukemic environment is preserved whereas mature blood cells cannot be produced due to the exhaustion of HPCs. Therefore, these data yield new insights into the pathogenesis of Notch1-involved T cell leukemia and may guide better clinical management for this type of malignancy.
MATERIALS AND METHODS

Mice
Wild type C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor, ME), and B6.SJL-Ptprc a Pepc b /BoyJ mice (B6.SJL) were purchased either from Taconic (Hudson, NY) or the Jackson Laboratory. CD45.1 + /CD45.2 + mice were the F1 generation of C57BL/6J and B6.SJL-Ptprc a Pepc b /BoyJ mice. All mice were maintained in the certified animal facility of the Hillman Cancer Center, University of Pittsburgh. The procedures involved in the animal work For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -5 -were approved by the Institutional Animal Care and Use Committee at all participating institutions in this study.
Transduction of murine primary bone marrow cells
The retrovirus vector containing the cDNA-encoding intracellular domain of Notch1 (ICN1) was Then the Lincells were re-enriched for expression of Sca-1 using the EasySep TM murine Sca-1 positive selection kit (Miltenyi Biotec, Auburn, CA). Transduction of lineage negative Sca-1 positive (Lin -Sca-1 + ) cells with ICN1 plasmid were performed as previously described with minor modifications. 5 The transduction efficiency was measured by flow cytometry.
Transplantation of the transduced cells and analysis of leukemia-bearing mice
Bone marrow nucleated cells (BMNCs; 1x10 7 /host) from B6.SJL mice at the age of 6-8 weeks were transplanted into lethally-irradiated (10Gy) female C57BL/6J recipients (6-8 weeks old) with or without 1x10 6 ICN1 plasmid-transduced Lin -Sca-1 + cells from C57BL/6J mice as indicated in Fig.1A . Due to the in vitro transduction and culture procedures, the majority of the cells transplanted into the recipients (detailed below) should be the progenies of Lin -Sca-1 + cells, not the Lin -Sca-1 + cells themselves. The recipients were followed up physically on a daily basis.
Peripheral blood (PB) sampling from the lateral tail vein was collected starting at 1 week post-transplantation for white blood cell (WBC) count, and the percentage of CD45.2 + GFP + cells was analyzed by flow cytometry using PE-Cy5.5-CD45.1 and PE-CD45.2 antibodies (eBioscience, San Jose, CA).
Flow cytometric analysis and cell sorting
Mouse bone marrow cells were obtained by flushing ilias, femurs, tibias and humeri as described. 6 The immunophenotypes for murine long-term repopulating HSCs 
In vitro clonal assay
CD45.1 + GFPcells from the leukemia and control groups were sorted at 2 weeks after transplantation for in vitro clonal assay and in vivo cBMT, respectively. For the CFC assay, the cells were placed in methylcellulose medium M3234 (StemCell Technologies, Vancouver, BC, Canada) supplemented with a mixture of recombinant cytokines including 50 ng/mL murine stem cell factor, 20 ng/mL murine interleukin-3, 20 ng/mL murine interleukin-6 (Peprotech, Rocky Hill, NJ) and 3 U/mL human erythropoietin (Amgen, Thousand Oaks, CA). Cells were plated in 24-well plates with a 0.5mL volume at a density of 2x10 4 cells/mL with 4 replicated wells. At day 10, the CFC colonies were counted under an inverted microscope and recorded as colony number in a specific lineage. For 5-fluorouracil (5-FU) exposure assay in vivo 72 hours after transplant, 150 mg/kg 5-FU was given (intravenous) at 12 hours before BM was harvested.
CD45.1 + GFPcells were sorted for CFC assay as described above.
The frequency of CAFC at day 35 was determined using limiting dilution assay as described. 10 Briefly, sorted CD45.1 + GFPcells were plated on an irradiated (15Gy) primary murine stroma in 
Apoptosis assay
Two weeks after transplantation, the whole bone marrow cells were isolated from each group and stained for PE-Cy7 conjugated with a mixture of lineage antibodies and PE-Annexin-V with congenic marker. The proportion of apoptosis cells was determined using flow cytometry.
Competitive and serial bone marrow transplant
The competitive bone marrow transplantation (cBMT) procedure was detailed in our previous publication. 11 Briefly, normal hematopoietic cells (CD45.1 + GFP -) were sorted from the BM of leukemia or control mice 2 weeks after transplantation. 2x10 6 sorted CD45.1 + GFPcells (test cells) along with an equal number of CD45.1 + /CD45.2 + BMNCs (competitive cells) were co-transplanted into lethally-irradiated (10Gy) female C57BL/6J recipients (n=5/group, 6-8 weeks old). After transplantation, blood was collected monthly. The endpoint was 6 months.
The relative contribution of test cells (CD45.1 + ) and competitive cells (CD45.1 + /CD45.2 + ) in reconstituted recipients was measured by flow cytometry using PE-conjugated anti-mouse CD45.1 and FITC-conjugated CD45.2 antibodies (eBioscience, San Jose, CA).
BrdU detection and cell cycle analysis
For in vivo analysis, the mice were given a single pulse administration of 5-bromo-2-deoxyuridine (BrdU) (BD Biosciences) at 72h after transplantation; an intraperitoneal injection of 100μg/g of BrdU was given at 2h before harvesting the BM cells. BrdU staining was For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -10 -quantitated using flow cytometry by combining surface staining to define BM subset with intracellular staining using the BrdU-APC staining kit following the manufacturer's instructions (BD Biosciences). For in vitro cell cycle analysis, the whole bone marrow cells from the leukemic or control group were isolated at 14 days after transplantation. Then the cells were permeabilized and stained with 1.67μmol/L Hoechst-33342 followed by 1μg/ml Pyronin-Y. The proportion of CD45.1 + LKS cells in G 0 phase was determined by flow cytometry with quantitation of DNA and RNA.
Cell proliferation tracing in vivo
Whole bone marrow cells from B6.SJL mice were labeled with 1μm of CFSE (Molecular Probes) as described. 12 1x10 8 CFSE labeled CD45.1 + cells were injected into lethally-irradiated C57BL/6J recipients with or without 5x10 6 developed ICN1 over-expressing leukemic cells (CD45.2 + ).
Seventy-two hours after transplantation, the recipients were sacrificed and the bone marrow cells were harvested and stained with PE-Cy5.5-conjugated CD45.1, PE-conjugated Sca-1, APC-conjugated c-Kit, and a mixture of PE-Cy7-conjugated lineage markers. Dead cells were identified with DAPI. The BD LSRII was used for data acquisition, and ModFit LT software (version 3.0, Verity Software House) was used for cell proliferation analysis. (Strategene, La Jolla, CA). Reverse transcription was achieved by using oligo-dT (12) (13) (14) (15) (16) (17) (18) and M-MLV reverse transcriptase (Ambion, Austin, TX). Real-time PCR reaction was done with SYBR green Master Mix (Finnzymes, Finland), 0.3µM of specific forward and reverse primers and normalized cDNA. The parameters for the thermal cycling of PCR were as follows: 15s at 95 0 C and 60s at 60 0 C, 45 cycles. All the primer sequences are listed in supplemental Table 2 .
RESULTS
Notch1 overexpression induces T-ALL with 100% penetrance.
We chose the Notch1-induced T acute lymphoblastic leukemia (T-ALL) model because the Notch1 signaling is thought to be a conserved pathway for self-renewal in HSCs and LSCs, 2 and the retrovirus-mediated overexpression of the intracellular domain of Notch1 (ICN1) was shown to be potent in T-cell leukemogenesis. 13, 14 We established the mouse T-ALL model in which lethally-irradiated recipients (C57BL/6J) were transplanted with 1×10 6 cells that were transduced with the MSCV-ICN1-IRES-GFP vector (starting with Lin -Sca-1 + cells) from C57BL/6J and 1×10 7 bone marrow nucleated cells (BMNCs) from B6.SJL mice ( Fig.1A) . Those recipients accumulated a double positive population (CD4 + CD8 + ) of immature T cells in the peripheral blood (PB) and bone marrow (BM) from the Notch1-transduced cells as early as 7 days after transplantation (Supplemental Fig.1 ). Two to 4 weeks after transplantation, white blood cells (WBCs) in PB and BM cellularity dominated by GFP + cells were increased in a temporal fashion ( Fig. 1B-D) .
Gross examination of tissues from the sick mice revealed splenomegaly, hepatomegaly, and lymphadenopathy, due to extensive organ infiltration by CD4 + CD8 + For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -12 - lymphoblasts. This robust leukemia model, in which 100% of the mice that received Notch1 over-expressing cells developed T-ALL within 6 weeks ( Fig. 1E ), permitted us to study the kinetics of co-transplanted normal hematopoietic cells (CD45.1) in a leukemic host from the onset of the disease.
Hematopoietic suppression at the stem cell and progenitor cell levels in leukemic mice.
To document the disrupted growth of normal hematopoietic cells during leukemia development, we monitored the kinetics of co-transplanted normal hematopoietic cells that expressed CD45.1 (Fig. 1A) . Using the Notch1-induced leukemia model, we examined the percentage of CD45.1 + cells in both PB and BM one week after transplantation. The results showed that in contrast to the rapid proliferation of the GFP + leukemic cells, the percentage of CD45.1 + cells declined dramatically ( Fig. 2A-B ). The average percentage of CD45.1 + cells in PB was 43.67% ± 4.14% frequency of the HPC-enriched Linpopulation was statistically higher than that in the control group. After the second week, the frequencies of both the LKS and Lincell populations became lower in the leukemia group than that in the control group (Fig. 2C-D) , while LKS cells in both groups continued to proliferate. At the fourth week, CD34 -LKS (Long-term repopulating HSC, LT-HSC), CD34 + LKS (short-term repopulating HSC, ST-HSC) and LKS -(differentiating HPC) were significantly lower in the leukemic BM than in the control group as measured by either the frequency or the absolute yield of each population ( Fig. 2E-F ). The input (CD45.1 + CD34 -LKS) and output (CD45.1 + LKS) cells harvested 2 weeks after transplantation were measured. The yield of LKS cells per initial CD34 -LKS in the leukemic host was 5 times lower than that in the non-leukemic but irradiated recipients (Supplemental Table 1 ). An independent assessment for HSC quantitation with the SLAM markers 15 also confirmed the significant inhibition of HSC growth in the leukemic host (Supplemental Fig. 2 ). More specifically, to exclude the possibility that the decreased frequency of the primitive cells in the leukemic marrow could be solely attributed to the absence of competition, we transplanted 1x10 7 BMNCs from B6.SJL (CD45.1 + ) along with a 100-time higher dose of BMNCs from C57BL/6J (1x10 8 , CD45.2 + ) than that of the leukemic cells into the lethally-irradiated control recipients (C57BL/6J). The frequency of HSCs (defined as CD150 + CD48 -LKS) in the leukemic group was still statistically lower than that in the control group (Supplemental Fig. 2 ).
We also performed in vitro clonal functional assays. CD45.1 + cells from leukemic and control groups 4 weeks after transplantation were isolated for the assessment of colony-forming cells For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -14 -(CFCs) and cobble-stone area forming cells (CAFCs) (Fig. 3A) . Notably, the frequency of CFCs was dramatically lower in the leukemic group (Fig. 3B ). Moreover, both groups showed detectable CAFC activity in the long-term culture system, but the CAFC frequency at day 35 during the culture from leukemia-bearing mice was approximately 4 times lower than that of the cells from the control mice (P<0.05) (Fig. 3C) . Together with the phenotypic analysis ( Fig. 2 C-D), these data provide direct evidence for the progressive suppression of hematopoietic cell growth during leukemia development, although the kinetics of HSC and HPC seemed to differ at the early stage.
Functional preservation of HSCs in leukemic marrow.
HSC is best defined by its ability to reconstitute the hematopoiesis of a lethally-irradiated recipient. 16 Given the significant suppression of normal HSCs and HPCs during leukemia development as assessed by phenotypic analysis and in vitro culture, we next tested whether the repopulating ability of normal hematopoietic cells from a leukemic environment was decreased in a new non-leukemic host. We co-transplanted equal numbers of CD45.1 + cells isolated from either a leukemic or a control group (2 weeks after transplantation) along with competitor cells (BMNCs freshly isolated from mice with a CD45.1 + /CD45.2 + phenotype) into lethally-irradiated C57BL/6J recipients. Because the repopulation unit (RU) in an unmanipulated C57BL/6J mouse has been well documented, 16 a fixed number of competitor cells (2×10 6 ) can serve as a standard measure against which the input cells from both groups can be compared. PB was collected 1-6 months after competitive bone marrow transplantation (cBMT), and the relative For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -15 -contribution to hematopoiesis of CD45.1 + cells isolated from both the leukemic and control groups was quantified using flow cytometry based on distinct congenic surface markers (CD45.1 + vs. CD45.2 + ). Unexpectedly, CD45.1 + cells isolated from the leukemic hosts engrafted better than the cells isolated from the non-leukemic control recipients. The level of CD45.1 + cells gradually increased after transplantation and stabilized at 3 months. Six months after cBMT, the level of CD45.1 + hematopoietic cells from the leukemic environment was more than 3 times higher than that from the control group (38.45% vs 11.40%) ( Fig. 4A ). This indicates no apparent defect in the hematopoietic potential of the residual normal HSCs isolated from the leukemic environment. A multilineage analysis of PB from cBMT recipients was performed to determine whether the HSCs in the leukemic environment maintained their ability to give rise to both myeloid and lymphoid lineages. The myeloid cells (granulocytes and monocytes) were immunophenotypically defined by Mac-1 + , the T cells by CD3 + , and the B cells by B220 + (Fig. 4B) . At the endpoint of 6 months after cBMT, the average level of CD45.1 + cells isolated from leukemic BM was about 10-fold higher than that of cells from the irradiated but non-leukemic environment (44.87% vs. 4.68%) ( Fig. 4C-D) . Consistent with this finding, the number of HSCs/HPCs from the leukemic environment was significantly higher than that from the control environment in the new recipients (Fig. 4E ).
Increased proliferation of normal hematopoietic progenitors upon exposure to leukemic marrow.
The marked decrease of normal hematopoietic cells in leukemic marrow may be due to transplantation, 18 we used the Sca-1 marker to define a relatively primitive state within the Linpopulation and found that 72 hours after transplantation, the CD45.1 + Lin -Sca-1 + cells co-transplanted with the leukemic cells underwent more cell divisions than the control cells (Fig.   5A ). This suggests that HPCs in the leukemic environment have a more active cycling status.
To determine the actual cycling status of the hematopoietic primitive cells under leukemic stress, mice in the leukemia and control groups were then pulsed with 5-bromo-2-deoxyuridine (BrdU) 72 hours after transplantation of the leukemic cells. CD45.1 + Lin -Sca-1 + cells were analyzed for BrdU incorporation 2 hours after injection. As shown in Fig. 5B , BrdU + Lin -Sca-1 + cells were significantly more abundant in the leukemic group than in the control group. Furthermore, we utilized the anti-metabolic reagent 5-fluorouracil (5-FU) to functionally measure the cells in S-phase. Seventy-two hours after transplantation, CD45.1 + GFPcells were isolated for CFC assay. While the CFC frequency increased significantly in leukemic marrow, there was a more
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -17 -dramatic reduction of the CFC yield after 5-FU treatment (Fig. 5C) , thus confirming the result of BrdU incorporation (Fig. 5B) . These cell cycle measurements, together with the CFC yields, are also consistent with the finding that CD45.1 + Lincells were more abundant in leukemic mice at the early stage (Fig. 2C) .
To exclude the contribution of apoptosis, we then stained for the apoptotic marker, Annexin V, in the cell population after transplantation and found no statistical difference in the apoptotic fraction between the hematopoietic cells from the leukemic environment and the cells from the control environment (Supplemental Fig. 3 ). This suggests that apoptosis may not be the main reason for the decrease of hematopoietic cells in the leukemic environment.
Increased quiescence of normal HSCs in leukemic hosts
It is known that relative quiescence is associated with the quality of stem cells in adults. 10, 11 To understand why HSCs from leukemic BM displayed higher levels of reconstitution than those isolated from the control mice when transplanted into non-leukemic new recipients, the quiescent fraction of HSCs in cell cycle was examined using the RNA dye pyronin Y (PY), which has been used as a measure for stem cell quiescence (G0 phase in cell cycle). 19 20 While there was no significant difference in the cycling fraction (S + G2/M) as assessed by the DNA dye Propidium Iodide (PI) (Fig. 6A ), CD45.1 + LKS cells from leukemia-bearing hosts demonstrated a larger fraction in G0 phase (PY low in the continuum) as opposed to that in G1 phase (Fig. 6B) , thereby suggesting that the leukemic environment is able to prevent quiescent HSCs from moving into Potential molecular players underlying the increased quiescence of the HSC pool were explored by examining several known cell cycle inhibitors including p18 INK4C , p21 Cip/Waf1 and p27 Kip1 (p18, p21 and p27 hereafter) in tissue stem and progenitor cells. 10, 12, 21, 22 As demonstrated in our previous studies, 11, 21 p21 maintains HSC quiescence in at least some mouse strains, whereas p27 primarily controls the proliferation of HPC. However, p18 and p21 play opposite roles in regulating HSC self-renewal. CD45.1 + LKS cells were harvested 2 weeks after initiation of leukemogenesis ( Fig. 1A) for the analysis with real-time RT PCR. There was a decrease in p18 expression in the cells from leukemic hosts compared to the control cells. However, p21
expression was significantly increased in the LKS cells isolated from a leukemic environment.
Consistent with this, its upstream regulator, Gfi-1, 23 was more dramatically increased. In contrast, there was no statistical difference in p27 expression between the cells from leukemic and control marrow (Fig. 6C) . Therefore, the altered expression of these cell cycle regulators may contribute to an underlying molecular basis for the more quiescent state and preserved self-renewal potential of HSCs in leukemic marrow. This mechanism could prevent normal HSCs from overly reacting to the leukemic environment and better maintain the potentiality of HSCs (Supplemental Fig. 4 ).
DISCUSSION
In summary, normal HSCs and HPCs are progressively suppressed during leukemogenesis.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -19 -While HPCs rapidly overreact to leukemic bone marrow with a more actively cycling status, it causes the exhaustion of HPC pools. In contrast, the function of HSC is better preserved at least in part due to increased quiescence in cell cycle. Therefore, HSCs and HPCs have distinct responses to a leukemic environment. Our findings may not only be able to model Notch1-induced leukemia, which is associated with more than 50% of T-ALL in children, 24 they may also have implications to studying other types of leukemia or cancer via a unique approach.
Our study demonstrates that the reduction in the number of blood cells in a leukemic environment is largely due to the impairment of HSC/HPC repopulation. Evolving leukemic cells cause disruption to the BM structure, which may interrupt the physiological interaction between HSCs and their niches. As a consequence, the responsiveness of normal HSCs and HPCs to cytokines may be altered. 25, 26 It has been reported that leukemic cell growth disrupts normal HPC niches in BM and creates an abnormal response to microenvironments that sequester transplanted human HPCs in a xeno-graft model. 13 Based on our current study, this response could be heightened during the early stages of leukemogenesis (Fig. 2C, Fig.5 ) and decreased at a later stage ( Fig. 2C-F) . Importantly, our study documents for the first time that normal HSCs can be reversibly suppressed by a leukemic environment. The compartment of normal HSCs in a leukemia host can be kept in a more quiescent state with preserved self-renewal potential, while normal HPCs may be exhausted after undergoing an accelerated proliferation. Therefore, when more quiescent HSCs from a leukemic environment are seeded into a non-leukemic or perhaps minimally leukemia-loaded hematopoietic microenvironment, For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -20 -they re-enter the cell cycle and the self-renewal potential of HSCs can be fully revealed (Supplemental Fig. 4 ). This model underscores the importance of host environment or condition in dictating a specific functional state of tissue stem cells and more specifically, it is also consistent with the rapid recovery of normal hematopoiesis in leukemia patients after an effective chemotherapy.
It should be noted that in our current study, young mice were used and the period of latency of leukemia was short. Thus, we cannot generalize our conclusions to leukemia development in elderly mice. Our previous work, in which HSCs and T leukemic cells were transplanted for multiple rounds over a 2 to 3 year period, demonstrated that normal HSCs in leukemic mice were no longer functional at later stages as assessed by both in vitro and in vivo assays. 9 In our present study, normal HSCs recovered from the leukemic environment were still highly functional after transplantation into new non-leukemic hosts. The difference in performance between the HSCs in these 2 studies is likely due to the different proliferation history of the stem cells. HSCs that remain in a leukemic environment may experience less proliferation than control cells, which may contribute to their ability to better repopulate after the second transplantation. In addition, in our current study, we used lethally-irradiated recipients, which may impact the engrafted HSCs via the bystander effect of irradiation (Shen H. et al., Manuscript under submission). But this potential confounding factor should be minimized due to our proper control, in which normal hematopoietic cells alone were transplanted into irradiated recipients (Fig. 1A) .
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -21 -While hematopoietic suppression is a general feature of leukemogenesis, the mechanisms that lead to the suppression and especially to the better performance of donor HSCs in secondary recipients may be context-dependent. A previous study by others showed that the size of the normal HSC compartment was unaffected in the B-ALL induced by ETV6-RUNX1 or p190 BCR-ABL, whereas it was significantly reduced in the B-ALL induced by p210 BCR-ABL. 27 Therefore, the actual effects of a cancer environment on normal tissue stem cells are likely determined by multiple factors, including the type and stage of leukemia, the patient age, and the specific therapeutic regimen. Future studies on the underlying molecular pathways, especially in the context of a specific cancer environment, are needed. Such studies may eventually offer complementary approaches for the prevention and treatment of cancer. Each value is mean ± sd, ** P<0.01 (n=3 mice /group, t-test). (C). 5-FU assay. 150mg/g 5-FU was injected 12h before BM was harvested and then CD45.1 + GFPcells were isolated for the CFC assay 72h after transplantation. The total CFC colonies were counted at day 14 with microscopy. The data shown is from 1 of 2 independent experiments (n=3-5 wells), **, P<0.01. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
